C18 3'-sulfo Galactosylceramide-d3 (d18:1/18:0-d3) |
| Catalog No.GC90244 |
An internal standard for the quantification of C18 3’-sulfo galactosylceramide
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
C18 3'-sulfo Galactosylceramide-d3 (d18:1/18:0-d3) is intended for use as an internal standard for the quantification of C18 3'-sulfo galactosylceramide by GC- or LC-MS. C18 3'-sulfo Galactosylceramide is a member of the sulfatide class of glycolipids. It is a minor endogenous sphingolipid produced from C18 ceramide and UDP-galactose in the endoplasmic reticulum followed by sulfation in the Golgi apparatus.1 C18 3'-sulfo Galactosylceramide levels are increased in brain tissue isolated from mice with an arylsulfatase A deficiency (ASA-KO), particularly in lipid raft fractions.2,3 Plasma levels of C18 3’-sulfo galactosylceramide positively correlate with disability progression in patients with relapsing-remitting multiple sclerosis using the Expanded Disability Status Scale.4 It is also increased in plasma from patients with metachromatic leukodystrop (MLD).5 Brain levels of short-chain sulfatides, including C18 3’-sulfo galactosylceramide, decrease with age in mice and humans.2,6 As this product is derived from a natural source, there may be variations in the sphingoid backbone. [Matreya, LLC. Catalog No. 1536]
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *